rdf:type |
|
lifeskim:mentions |
umls-concept:C0001779,
umls-concept:C0021403,
umls-concept:C0042776,
umls-concept:C0332161,
umls-concept:C0439234,
umls-concept:C0681850,
umls-concept:C1548795,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2697811
|
pubmed:issue |
38
|
pubmed:dateCreated |
2008-9-1
|
pubmed:abstractText |
Live attenuated influenza vaccine (LAIV) is indicated for influenza prevention in persons 2-49 years of age. This study describes the incidence and duration of vaccine virus shedding and serum immune responses after receipt of LAIV.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0264-410X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
8
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
4940-6
|
pubmed:meshHeading |
pubmed-meshheading:18662737-Adolescent,
pubmed-meshheading:18662737-Adult,
pubmed-meshheading:18662737-Age Factors,
pubmed-meshheading:18662737-Antibodies, Viral,
pubmed-meshheading:18662737-Child,
pubmed-meshheading:18662737-Child, Preschool,
pubmed-meshheading:18662737-Demography,
pubmed-meshheading:18662737-Female,
pubmed-meshheading:18662737-Humans,
pubmed-meshheading:18662737-Influenza, Human,
pubmed-meshheading:18662737-Influenza A virus,
pubmed-meshheading:18662737-Influenza B virus,
pubmed-meshheading:18662737-Influenza Vaccines,
pubmed-meshheading:18662737-Male,
pubmed-meshheading:18662737-Middle Aged,
pubmed-meshheading:18662737-Time Factors,
pubmed-meshheading:18662737-Vaccination,
pubmed-meshheading:18662737-Vaccines, Attenuated,
pubmed-meshheading:18662737-Virus Shedding
|
pubmed:year |
2008
|
pubmed:articleTitle |
Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
|
pubmed:affiliation |
Kentucky Pediatric and Adult Research, Bardstown, KY 40004, United States. slblock@pol.net
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase IV
|